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3GLOBAL POLIO ERADICATION – PROGRESS 1999
Summary
T he global initiative to eradicate polio bythe end of 2000 has become the largestpublic health initiative in history, and is
spearheaded by WHO, Rotary International, U.S.
Centers for Disease Control and Prevention, and
UNICEF. During 1999, extraordinary progress
continued with the number of polio-endemic coun-
tries declining from 50 in 1998 to 30 in 1999. Of
the three types of poliovirus, type 2 poliovirus
reached the verge of extinction with the only known
remaining foci existing in northern India. Polio
incidence declined to the lowest levels ever in 1999,
although reported cases increased slightly to 7 012
due to improvements in surveillance and polio
outbreaks in Angola and Iraq. Existing challenges to
the initiative included maintaining high-quality
activities, gaining access to children in conflict
affected countries, and ensuring political and finan-
cial support until certification is achieved in 2005.
An additional challenge, ensuring sufficient oral
polio vaccine, emerged during 1999 as a result of
marked acceleration of immunization activities.
The public-private sector partnership supporting
the initiative expanded in 1999 to include the Bill
& Melinda Gates Foundation, Mr. Ted Turner’s
United Nations Foundation, the World Bank,
Aventis Pasteur, and De Beers.  r
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Global Polio Eradication – Progress 1999
T he global effort to eradicate polio is thelargest pubic health initiative in history.The initiative was launched in 1988 by
the World Health Assembly with the goals of erad-
icating polio while strengthening capacity to
control other major childhood diseases.
Extraordinary progress has been made to achieve
polio eradication by 2000 and global certification
of eradication by 2005. 
In 1988, polio existed in over 125 countries on five
continents, and more than 350 000 children were
paralyzed that year. By the end of 1999, the num-
ber of polio-infected countries decreased to 30
(Figure 1), polio was eliminated from another three
continents, and polio cases fell to 7 012 reported
(maximum estimated of 20 000). With the eradica-
tion of polio and the eventual cessation of polio
immunization, the world will save US $1.5 billion
per year. 
This report summarizes the polio eradication
initiative’s: 
(1) major highlights and accomplishments during
1999; 
(2) status of poliovirus transmission at beginning
of 2000; 
(3) status and quality of strategy implementation
of: national immunization days, acute flaccid
paralysis surveillance, Mop-up immunization
campaigns, the global laboratory network, rou-
tine immunization, and the Global Alliance for
Vaccines and Immunization (GAVI), 
(4) optimization of impact on health systems;
(5) preparations for the post-eradication era; 
(6) partnership support and advocacy making this
initiative a reality;
(7) financial resource requirements; and
(8) challenges and priorities during the Mop-up
and Certification Phase, 2000 – 2005. r
Figure 1: Polio eradication progress, 1988-1999*
350 000 cases
* as of 13 April 2000
7 012* cases
1988
1999
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1999 Highlights and Accomplishments
November 1999: A First Anniversary of the
Last Polio Case in Europe. Melik Minas, the
last case, was 33 months old when paralyzed with
polio in November 1998 in Turkey. He had never
been vaccinated. Following case identification, a
massive Mop-up immunization campaign was
conducted in southeast Turkey and neighbouring
areas of Iran, Iraq, and Syria. No additional cases
have been reported since.
Spring 1999: Pakistan & Nigeria launched
the largest ever house-to-house mass
immunization campaigns. Over 42 million
children were reached, many vaccinated for the
first time.
24 May 1999: All Member States at the
World Health Assembly unanimously
agreed to accelerate polio eradication
activities, and by September, all major endemic
countries had adopted the strategy. The number of
National Immunization Days (NIDs) was
increased, and a house-to-house immunization
strategy was added to NIDs to reach and vaccinate
over 470 million children.
August to October 1999: The UN Secretary-
General led negotiations that established
“Days of Tranquillity” in the Democratic
Republic of the Congo. Access was established,
and over 8 million children vaccinated. 
Sensitivity of acute flaccid paralysis (AFP)
surveillance has doubled since 1997, with
reported AFP cases increasing to nearly 29 000
globally and more than 50 000 stools tested for
polio.
Fall / Winter 1999: In India, a record 147
million children were immunized each
round during four NIDs, and over one billion
doses of oral polio vaccine (OPV) were
administered. India is the largest polio reservoir
and accounted for approximately 40% of all polio
cases reported during 1999. 
STOP (Stop Transmission of Polio) teams
were established and deployed to 15
countries to work closely with national public
health staff to improve capacity for polio
surveillance and the quality of NIDs.
Every polio endemic country conducted
NIDs. Sierra Leone completed the list by
conducting NIDs in 1998/99, when a cease-fire
ended 8 years of civil war. 
The Bill & Melinda Gates Foundation and
Mr. Ted Turner’s United Nations Foundation
donated US $78 million in new support.
Other new partners – the World Bank, Aventis
Pasteur, De Beers – brought an additional US $56
million. Canada, the European Union, Germany,
Italy, the United Kingdom, and the United States
markedly increased their support.
Vitamin A was administered during polio
immunization campaigns in over 50
countries.  r
Melik Minas, the last known polio case in the WHO European Region
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Status of Polio Transmission
E xtraordinary progress towards polio eradi-cation continued in 1999. The number ofknown or suspected polio-endemic coun-
tries decreased from 50 countries in 1998 to 30 in
1999. Type 2 polio (one of three types of poliovirus)
is on the verge of extinction with the only known
foci existing in northern India. Polio incidence
declined to the lowest levels ever in 1999, although
reported cases increased slightly to 7 012 due to
improvements in surveillance and a large outbreak
in Angola. Polio was eliminated from the fifth of
the seven continents with over a year elapsing since
the last European case.
Polio-free Regions
Three of the six WHO Regions representing 115
countries have been polio-free for more than one year. 
Americas Region: 
The last case of polio in the Americas Region
occurred in 1991. During 1999, a polio outbreak in
Angola appeared to threaten the polio-free status of
the Americas when two suspected cases were report-
ed in Brazil. Neither case was confirmed. 
Western Pacific Region: 
The last case of endemic polio in the Western
Pacific Region was reported in 1997. A 1999 case in
China was associated with an imported poliovirus
from India. Implications for Regional certification
will be considered during 2000. No Region is safe
from polio until all Regions are polio-free.
European Region: 
The last known case of polio in the European
Region occurred in Turkey in November 1998.
Remaining Polio-endemic
Regions
African Region (46 countries)
Twenty of the 46 countries in the Region are
endemic or probably endemic. In 1999, 2 825 polio
cases were reported in the African Region; 238 of
these were laboratory-confirmed (Table 1).
Poliovirus circulation in the African Region is con-
fined largely to the Horn of Africa, and west and
central Africa. The most intense transmission
occurred in Nigeria, Chad, and the Democratic
Republic of the Congo. A summary of polio in the
WHO Region 1998 1999
African Region 1 699 4 750
American Region 1 662 1 646
Eastern Mediterranean Region 2 216 2 979
European Region 1 308 1 786
South East Asian Region 11 352 11 816
Western Pacific Region 6 420 5 766
Global total 24 657 28 743
AFP reported
1998 1999
0.30 0.70
0.95 0.93
0.88 1.13
0.94 1.24
1.25 1.52
1.43 1.27
1.08 1.30
Non-polio 
AFP rate
1998 1999
36% 31%
73% 68%
64% 69%
67% 75%
60% 71%
86% 86%
67% 67%
Percent AFP
with adequate specimens
1998 1999
993 (93) 2825 (238)
0 0
555 (230) 833 (463)
26 (26) 0
4775 (1942) 3353 (1160)
0 1(1)**
6349 (2294) 7012 (1862)
Confirmed Polio
(wild virus confirmed)
Table 5: Reported AFP cases, surveillance quality indicators and confirmed poliomyelitis cases 1998-1999, by WHO Region*
* Data as of 6 March 2000
** Importation into China, probable source was India
WHO African Region, by countries in special situ-
ations and by epidemiologic block, follows.
Countries in Special Circumstances
Nigeria reported 974 cases, including 94 laborato-
ry-confirmed cases in 1999 and continues to have
intense polio transmission in nearly all parts of the
country. Nigeria is a major reservoir of poliovirus
and exports poliovirus to countries throughout west
and central Africa. 
Angola reported 1 103 cases, including 89 deaths,
as a polio epidemic swept the country in early 1999.
Displaced children who had never been vaccinated
were at the highest risk during this outbreak. 
Democratic Republic of the Congo (DR Congo)
reported 45 cases in 1999 and is a major reservoir of
poliovirus with reported cases understating actual
incidence due to inadequate surveillance in the
majority of the country. Poliovirus transmission in
DR Congo represents a continuing threat to the
apparent polio-free status of neighbouring countries
in east Africa. 
Ethiopia reported 133 cases of polio in 1999 but
none was laboratory confirmed. Despite the lack of
poliovirus isolates, the real polio epidemiologic
situation remains unclear due to inadequate surveil-
lance sensitivity and laboratory capacity. 
Four Epidemiologic Blocks of the AFRO Region
Southern Africa Block (14 countries, including 5
island nations)
All countries of the Southern Africa Block appear
polio-free. The last confirmed case in this block was
reported in 1997 in Madagascar.  However, there is
a high risk of unrecognised low-level polio trans-
mission in Mozambique, Madagascar, and Malawi,
in particular, because surveillance remains inade-
quate. The cessation of NIDs in some southern
African countries coupled with poor routine oral
polio vaccine (OPV) coverage increases the risk that
polio may become re-established.
East Africa Block (7 countries)
The East Africa Block countries of Zambia,
Tanzania, Uganda, Kenya, Rwanda, and Burundi
appear polio-free. The last confirmed cases occurred
in Uganda in 1996, and in Zambia and Tanzania
in1995. Polio transmission continued to occur at
low levels in Eritrea, which reported seven cases in
1999. However, every country is at risk of importa-
tion and reestablishment of polio transmission
because all countries border an endemic area and
have low coverage with the three childhood doses of
OPV (OPV3).
Central Africa Block (6 countries)
Intense polio transmission continues in Chad,
which reported 105 polio cases, of which 35 were
laboratory-confirmed. Sixty percent of AFP cases
with specimens collected were positive for
poliovirus in that country. Cameroon and Central
African Republic appear to have low levels of polio
transmission, but remain at risk due to proximity to
countries with high transmission levels. Although
Congo, Gabon, and Equatorial Guinea had no viro-
logically confirmed cases, surveillance is extremely
weak and there is a very high risk of unrecognised
transmission. 
7
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Melita with her baby Johnny in Angola
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West Africa Block  (15 countries)
Polio transmission continues in this Block, and is
most intense in Benin, Liberia, Niger, and probably
Sierra Leone. Ghana, Mali, Senegal, Sierra Leone,
and Togo reported low levels of transmission with
laboratory-confirmed cases. Due to low levels of
poliovirus transmission and good AFP surveillance
quality, six countries are poised to enter the Mop-
up phase of eradication (Cote d’Ivoire, Ghana,
Guinea, Mali, Senegal, and Togo.) Suboptimal AFP
surveillance quality limited detection of probable
virus in Burkina Faso, Guinea-Bissau, and Gambia.
Eastern Mediterranean Region (23 countries)
In 1999, 833 cases were reported in the Eastern
Mediterranean Region (Table 1), including 463 lab-
oratory-confirmed cases. Polio transmission contin-
ues to be intense in Pakistan, which reported 501
cases, and is a major reservoir for poliovirus.
Afghanistan had widespread circulation with 150
reported cases, and poliovirus with marked geno-
typic similarity to virus in Pakistan. Poliovirus from
Afghanistan was epidemiologically linked to the
three polio cases reported in Iran during 1999.
Although two of these appear to have been import-
ed viruses, low-level endemic transmission of
poliovirus may be continuing. After reporting zero
cases in 1998, a widespread polio outbreak occurred
in Iraq with 127 reported cases, including 72 labo-
ratory-confirmed polio cases.
Sudan (51 cases), and Somalia (16 cases) also
reported polio cases. Egypt has made substantial
progress with the lowest transmission ever, however
focal transmission continued (in Assiut and Minya)
in the Upper Nile. 
South East Asia Region (10 countries)
In 1999, 3 353 polio cases were reported in the
South East Region, including 1 160 laboratory-
confirmed cases (Table 1) from four countries.
Reported polio cases in India declined to 2 802
cases, a 35% decline from 1998. Intense transmis-
sion continues to occur in Bihar and Uttar Pradesh,
two States which are also the only known remaining
foci of poliovirus Type 2 transmission. Polio trans-
mission has markedly decreased in the southern
part of India which is now entering the Mop-up
Phase of polio eradication. 
Bangladesh reported 397 cases in 1999. Despite
this large number, genetic typing demonstrated that
several poliovirus lineages are nearing extinction,
and the biodiversity of the virus has substantially
decreased as compared with previous years. Nepal
reported only one laboratory-confirmed case in
1999, and appeared to have only focal transmission
along its border with India. In Myanmar, four cases
due to an imported virus were detected with subse-
quent rapid mass vaccination. No additional cases
have been reported. The polio situation in DPR
Korea remains unclear due to lack of surveillance
and laboratory data.  r
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Delivering OPV in Kowkaban,Yemen
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National Immunization Days 
n NIDs or sub-national immunization days
(SNIDs) were conducted in 83 countries,
reaching more than 470 million children
(Figure 2). Full NIDS were conducted in
70 countries, often with SNID rounds in high-
risk areas. In India alone, over one billion OPV
doses were distributed during four NIDs and
two SNIDs (October 1999 to March 2000).
Thirteen mostly polio-free countries in the
European and Western Pacific Regions con-
ducted SNIDs only.
n Vitamin A supplementation was included in
50 of the 83 countries conducting supplemen-
tary immunization activities in 1999.
n In a major policy shift to accelerate polio erad-
ication activities, the number of NIDs rounds
was increased in reservoir and other priority
countries (Figure 2). Afghanistan and India
conducted four rounds of NIDs, with two
additional rounds of SNIDs in India in early
2000. Three rounds of NIDs were conducted
in Angola and DR Congo. However, many
children were missed in Angola due to internal
disturbances.
Status and Quality of Strategy Implementation
Figure 2: Accelerated polio immunization activities 1999-2000
Extra intensified NIDs rounds
NIDs + SNIDs or ‘Mop-ups’
DEPARTMENT OF VACCINES AND BIOLOGICALS
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n The quality of NIDs and SNIDs was improved
by strengthened planning at provincial and
district levels, and by extensive use of house-to-
house vaccination strategies. These “intensi-
fied” NIDs and SNIDs were featured in
Afghanistan, Pakistan, and Nigeria, with
resulting in increases of as much as 50% in the
number of children reached in some provinces.
n The quality of NIDs was threatened by a glob-
al OPV shortfall that resulted from uncertain-
ty of supply, cancelled shipments, and resched-
uling of major orders. Many countries were
adversely affected by the uncertainty of the
vaccine supply, including cancelled or delayed
rounds in Chad and Ghana, receipt of differ-
ent presentations of the vaccine (e.g. Spanish
labels in non-Spanish speaking countries, 10
instead of 20 dose vials), and routine OPV
orders postponed.
n Evaluation of the quality of NIDs was
improved by monitoring the number of chil-
dren vaccinated for the first time (zero-dose
monitoring), process evaluations, and limited
use of coverage surveys. However, high-quality
AFP surveillance remains the gold standard for
evaluating the quality and effectiveness of
NIDs and SNIDs.
Acute Flaccid Paralysis (AFP)
Surveillance 
AFP Overview
AFP surveillance is used to detect polio cases and
reaches certification standard if the non-polio AFP
rate is ‡ 1 / 100.000 population aged < 15 years,
adequate specimens are collected from 80% or
more of AFP cases, and specimens are evaluated on
a timely basis in accredited laboratories (Table 1).
Figure 3: Endemic or recently endemic country priorities for improving surveillance in 2000*
Good quality surveillance or marked improvement*
Inadequate surveillance*
* data as of February 2000, WHO/HQ
11
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High-quality surveillance was achieved by the
Western Pacific Region as well as the European,
South East Asia, and Americas Regions. At
Regional and country levels, delay in achieving cer-
tification standard surveillance can result in late
detection of polio infected areas. Therefore high
priority must be given to achieving rapidly certifi-
cation standard surveillance.
Polio-Endemic Regions
n The African Region improved surveillance
dramatically, with the non-polio AFP rate
more than doubling from 0.30 in 1998 to 0.70
in 1999.  However, only 31% of AFP cases had
adequate specimens collected. Priority coun-
tries for surveillance improvement include
Madagascar, Malawi, Mozambique, and
Ethiopia (Figure 3).
n The Eastern Mediterranean Region
improved surveillance as the non-polio AFP
rate increased to 1.13 from 0.88 in 1998.
Among the six polio-endemic countries, Egypt,
Iraq, and Pakistan achieved a non-polio AFP
rate > 1, with Afghanistan close at 0.95.
Somalia and Sudan reported rates of 0.79 and
0.52, respectively. Region-wide, the percentage
of cases with adequate specimens rose slightly to
69% in 1999 from 64% in 1998. The contin-
ued surveillance achievements in Afghanistan,
Somalia and Sudan demonstrate that high qual-
ity surveillance can be implemented even in the
most difficult circumstances.
n The South East Asia Region increased its
non-polio AFP rate to 1.52 in 1999 from 1.25
in 1998. Two of the four polio-endemic coun-
tries, India and Nepal, achieved the standard
for reported non-polio AFP rates with rates of
1.8 and 1.9, respectively. Nepal substantially
improved surveillance, with their non-polio
AFP rate increasing from 0.41 in 1998 to 1.91
in 1999. Bangladesh also improved its AFP
surveillance from 0.33 in 1988 to 0.63 in
1999. AFP surveillance in DPR Korea remains
inadequate. Region-wide, the percentage of
cases with adequate specimens increased to
71% in 1999 from 60% in 1998. During
2000, priority countries for improving surveil-
lance are DPR Korea, Myanmar, and
Bangladesh (Figure 3).
Mop-up Immunization Campaigns
Mop-up is the “end game” strategy for polio
eradication where high-quality AFP surveillance
information is used to identify remaining pockets of
virus transmission. Intense house-to-house immu-
nization activities are then targeted to eliminate the
final chains of virus transmission. During early
1999, Mop-up was conducted in southeast Turkey
and neighboring provinces of Iran, Iraq, and Syria
following a case reported in Turkey in late 1998. No
additional cases have been reported since then in
Turkey, Iran, or Syria. 
NOTE: Although house-to-house immunization
was conducted during NIDs or in response to a
detected case in many countries during 1999, this
was intended to improve the quality of activity and
reach unreached children. It did not meet the
criteria of classic Mop-up to stop the final chains of
poliovirus transmission.
Status of the Global Polio
Laboratory Network
Standard guidelines, procedures, cell lines and
reagents have been established and implemented in
laboratories at each level of the network. During
1999, almost all stool specimens from AFP cases
were processed in WHO-accredited laboratories.
Over >50 000 specimens were processed for viral
isolation, >3 000 poliovirus and >10 000 non-polio
enterovirus were isolated, serotyping and intratypic
differentiation were carried out on all poliovirus
isolates, and genomic sequencing information pro-
vided on nearly all programmatically important
wild poliovirus isolates. The India and Nigeria
country experiences illustrated the dramatic
increase in laboratory workload between 1997 and
1999 (India from 1 570 specimens in 1997 to
15 800 specimens in 1999 [a >10-fold increase],
and Nigeria from 71 specimens in 1997 to 923
specimens in 1999 [a 13-fold increase]). 
At end of 1999, 123 (83%) laboratories had inter-
national phone or fax lines, and/or access to email,
but 25 (17%) continued to have inadequate com-
munications. Arrangements are being made to
ensure that wild-type poliovirus isolates are being
shipped in a timely and frequent manner to special-
ized laboratories that have the capacity to sequence
this isolates. 
DEPARTMENT OF VACCINES AND BIOLOGICALS
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Figure 4: Global Laboratory Network for polio eradication, 2000
Specialised Reference Laboratory
Regional Reference Laboratory
National/Sub-national Laboratory
Proposed National Laboratory
As of January 2000
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Routine Immunization 
Both reported and survey-confirmed routine
immunization coverage with OPV3 is low and stag-
nating in the remaining priority countries.
Improvements in routine immunization are urgent-
ly needed, and efforts to accelerate polio eradication
provide a useful opportunity to boost routine
immunization, strengthen EPI target disease sur-
veillance together with AFP surveillance, improve
the cold chain, and train health workers and mid-
level program managers. The absence of reliable
basic immunity to polio through routine immu-
nization is one of the main reasons underlying the
need for additional nationwide immunization cam-
paigns to reach the eradication target. (Figure 5)
The Global Alliance for Vaccines
and Immunization (GAVI)
The Global Alliance for Vaccines (GAVI) was estab-
lished during 1999 as a major new initiative that
will facilitate polio eradication, especially by
improving routine immunization coverage. GAVI
has representation from all immunization partners,
including WHO, UNICEF, World Bank, national
governments, bilateral donors, foundations, and
corporations. GAVI’s objectives are to achieve a new
broader and revitalised EPI, and all immunization
partners are a part of GAVI. GAVI is supportive of
immunization in general and of the polio eradica-
tion initiative in particular. The challenge is to
ensure that WHO, UNICEF, and others – as GAVI
partners – develop strategies that take full advantage
of renewed international support for immunization
to finish polio eradication. The lessons learned and
infrastructure developed from polio eradication
must be utilized in fulfilling GAVI’s objectives. 
Country level activities of GAVI partners will be
coordinated closely with those of polio eradication.
In polio-free countries, GAVI’s objectives are to
facilitate the introduction of new vaccines and pro-
mote certification standard surveillance. In polio-
endemic countries that will conduct additional
NID rounds, GAVI partners will ensure that new
activities complement NIDs and do not disrupt
polio eradication. In addition, GAVI will support
strengthening of routine immunization services. In
countries believed to be polio free but with poor
AFP surveillance, the GAVI initiative will be used
to strengthen AFP surveillance through the multi-
year immunization plan that will be developed and
implemented.  r
Figure 5: Polio-endemic countries and low OPV3 coverage
Known or portable poliovirus at end 1998
Very high risk
OPV3<80% in large areas or nationwide
DEPARTMENT OF VACCINES AND BIOLOGICALS
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T he 41st World Health Assembly in 1998committed WHO to the goal of polioeradication by the year 2000 “...in ways
which strengthen national immunization pro-
grammes and health infrastructure.” WHO, togeth-
er with partner organizations, has continued efforts
to ensure that polio eradication activities comple-
ment and support efforts to strengthen routine
health services. In December 1999, WHO con-
vened a meeting, “The Impact of Targeted
Programmes on Health Systems: A Case Study of
the Polio Eradication Initiative” to present and
share findings of these case studies and other assess-
ments. Key studies and findings include:
n WHO, with support from USAID and DFID,
initiated a study in 1997 to develop a method-
ology and country case studies in Tanzania,
Nepal, and the Lao People’s Democratic
Republic. These studies found both positive
and negative impacts of the polio eradication
activities, and concluded that with better plan-
ning and objectives, positive impacts could
increase and negative impacts could be
reduced.
n The All India Institute of Medical Sciences
Evaluation of Pulse Polio Immunization
Program concluded that the polio eradication
initiative had strengthened management
capacity, improved social mobilization, and
increased confidence in the health care system.
It recommended better planning to minimize
the disruptions from NIDs.
n A USAID-funded study found that the imple-
mentation of polio eradication activities was
not associated with a decrease in funding for
routine EPI in Bangladesh, Cote d’Ivoire, and
Morocco. Rather, overall funding for immu-
nization activities increased.
n A report on Lessons Learned in the
Development of the Global Polio Eradication
Network concluded that the principles of qual-
ity assurance and laboratory accreditation used
in the laboratory network can be used to
improve quality of other health programs.
n A UNICEF study in Benin and Niger found
no strong evidence about the impact of the
polio eradication initiative on routine cover-
age, but recognized missed opportunities to
link polio eradication with other programs,
and to strengthen EPI.
n There was broad recognition that NIDs have
served as a vehicle for Vitamin A supplementa-
tion. In AFRO, Vitamin A supplementation
has surged by >500% since NIDs were imple-
mented in 1996.
Although there is little reliable quantifiable data,
negative impacts of the polio eradication activities
that have been reported include disruption of rou-
tine EPI activities and disruption of other health ser-
vices. These could be reduced or avoided by better
planning, renewing the focus on routine immuniza-
tions, by linking AFP surveillance to surveillance for
other diseases, and by using training and supervision
for the polio eradiation initiative as an opportunity
for other health services. Other recommendations
from the WHO meeting include the following:
(1) A matrix framework of indicators developed for
the country case studies should be distributed
as a simple planning and assessment tool for
country managers.
(2) A “state-of-the-art” paper should be drafted to
compile existing documentation on the impact
of polio eradication.
(3) Efforts to document current gaps in knowledge
of the impact of polio eradication should be
initiated.  r
Optimizing the Impact of Polio Eradication
on Health Systems
15
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A fter twelve years, the polio eradication ini-tiative has reached every polio endemiccountry on earth, the burden of disease
has been dramatically reduced and wild poliovirus
transmission contained to a limited number of
countries. The progress achieved to date makes it
likely that polio will be eradicated worldwide in the
near future. Accordingly, WHO Vaccines and
Biologicals is now expanding its focus to deal with
the issues of the post eradication era: Containment,
Certification and Stopping Immunization.
Containment
Since there is no animal or environmental reservoir
for polioviruses, the only source of poliovirus after
human transmission ceases will be laboratories. To
prevent the possibility of an inadvertent escape of
wild virus from a laboratory, wild poliovirus stocks
must be stored in secure laboratory facilities. A plan
for containment of polioviruses was prepared in late
1998 and circulated widely for comment in the sci-
entific and biosafety communities. A final plan of
action has been prepared. It calls for national
biosafety authorities to inventory all stocks of
poliovirus and potentially infected materials.
Poliovirus strains should no longer be present in
facilities where their use is not essential. Strains of
scientific value should be moved to secure reposito-
ries. One year after the last wild poliovirus is iden-
tified all remaining stocks should be placed in max-
imum containment laboratories where essential sci-
entific work can continue. The procedures called
for in the containment plan are currently being field
tested in the American, European and Western
Pacific Regions.
Certification
The processes for certifying global polio eradication
were defined in 1995 at the first meeting of the
Global Commission for the Certification of the
Eradication of Poliomyelitis. Certification required
at least three years of zero polio cases under condi-
tions of good surveillance. AFP surveillance was to
be the primary surveillance tool.  The process called
for National Committees to prepare reports for
review by Regional Certification Commission,
which would, in turn, report to the Global
Commission. As of 1999, all Regions now have a
certification commission that has met to define the
Regional Processes. With the last indigenous case in
the Western Pacific Region occurring in March
1997, the Western Pacific Commission is preparing
to receive reports from its member states in the year
2000. The European Regional Commission has
begun reviewing preliminary reports from its mem-
ber states in anticipation of certifying that Region
free of polio in 2001, three years after the last case
in Turkey in November 1998. Although it has
begun to receive preliminary reports from the more
advanced countries in its Region, the Eastern
Mediterranean Region has affirmed that the Region
must be certified as a whole, emphasizing the need
to achieve rapid progress in the remaining endemic
countries. The African and Southeast Asian
Regional Commissions have met to plan their work
over the next years.
Stopping Immunization
Stopping immunization against polio is the ulti-
mate objective of the eradication initiative and
will yield annual global savings of US $1.5 billion.
A meeting was held in March 1998 to review exist-
Preparing for the Post-eradication Era
ing scientific data relevant to stopping immuniza-
tion. A research agenda was defined so that new
data could be developed using modern techniques
and to take advantage of opportunities presented by
the absence of circulating wild virus in developing
countries. Three foci were outlined: the potential
for vaccine derived viruses to continue circulating
after immunization is stopped, persistent shedding
of vaccine derived polioviruses among immunodefi-
cient persons and the need for new polio vaccines in
the post eradication era. As a result, a number of
research projects were initiated. A meeting was held
in April 1999 to review progress on these studies. In
addition, a meeting was planned for January 2000
to discuss new polio vaccines. Because manufactur-
ers will need 5-7 years lead time to ensure that
sufficient quantities of any vaccine other than the
current OPV will be available when needed, it is
anticipated that a meeting will be held in later 2000
to review new scientific data and recommend a
strategy for stopping immunization.  r
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Partnership Support and Advocacy
T he success of the polio eradication initia-tive hinges upon the successful partner-ship of the public and private sectors. The
partnership is spearheaded by WHO, Rotary
International, U.S. Centers for Disease Control and
Prevention, and UNICEF. The coalition is made up
of national governments; private foundations (e.g.
United Nations Foundation, Bill & Melinda Gates
Foundation); development banks (e.g. World
Bank); donor governments (e.g. Australia, Belgium,
Canada, Denmark, Finland, Germany, Italy, Japan,
UK and US), and corporate partners (e.g. Aventis
Pasteur, De Beers).
Rotary International
Through its Polio Plus programme, Rotary
International has been a key player in stimulating,
developing, and maintaining the global
poliomyelitis eradication initiative. By end of 2005,
Rotary estimates that its contribution to the initia-
tive will total US $500 million, as well as millions
of volunteer hours throughout the world to
promote and participate in polio eradication activi-
ties. During 1999, Rotary awarded grants totalling
US $32 million.
New Partnership Support 
n The Bill & Melinda Gates Foundation provid-
ed US $50 million and Mr. Ted Turner’s
United Nations Foundation granted US $28
million to strengthen the vaccine delivery
infrastructure and strengthen surveillance sys-
tems. 
n De Beers made a multi-year donation of
US $2.7 million to fund NIDs in Angola
during 1999 and 2000, targeting 3.3 million
children in six rounds of nationwide immu-
nization days.
n Aventis Pasteur (formerly Paster Merieux
Connaught) donated 50 million doses of vac-
cine (approximately US $5 million) for NIDs
in five countries affected by war (Angola,
Liberia, Sierra Leone, Somalia, and Sudan)
during 2000 – 2002. 
n The World Bank joined with the Government
of India to support the massive acceleration in
that country by reprogramming US $48 mil-
lion in health sector loans.
Increased Support from Existing
Partners
n Donor governments increased bilateral sup-
port to India, including the UK (US $62 mil-
lion), the European Union (US $6 million),
Germany (US $7.5 million), and Italy (US $1
million). India has the largest resource
requirements of any country, and usually
accounts for 35% of global external need in a
given year. 
n Canada pledged multi-year support to Nigeria
in the amount of C $6 million (US $4.2 mil-
lion). Nigeria is second to India in terms of
resources required for polio eradication, and
usually accounts for 15% of annual global costs. 
n In addition to the support targeted to India,
the UK government’s Department for
International Development also pledged to
support six of the ten priority countries that are
on the African continent (Angola, DR Congo,
Ethiopia, Nigeria, Somalia, and Sudan) with a
grant of £20 million (US $32 million). 
n The government of the United States (Centers
for Disease Control and Prevention) respond-
ed to the joint UNICEF-WHO appeal for
OPV with an additional commitment of
US $15 million for 2000. The government of
Japan is planning to increase its commitment
for OPV in 2000. 
DEPARTMENT OF VACCINES AND BIOLOGICALS
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Partnership Advocates for Polio
Eradication
During 1999, many civil-society partners joined
Rotary-led advocacy for polio eradication. 
n One of the world’s leading tennis stars,
Martina Hingis and star basketball player,
Dikembe Mutombo, with the National
Basketball Association’s Atlanta Hawks gave
high-profile support. Mutombo lent support
in his native DR Congo by visiting a hospital
to immunize babies and making Public Service
Announcements broadcast by Voice of
America.
n World-renowned British photographer Lord
Snowdon, who had polio, traveled to war-torn
Angola in May through the support of
De Beers to prepare and share with the world
photographic records of the 1999 polio out-
break.
n The Federation Internationale de Football
Association committed players and resources
toward the final stretch in efforts to “Kick
Polio out of Africa.” During 2000, messages
recorded by players will be broadcast across the
continent, billboard ads will carry messages,
and leaflets will be distributed at games. 
n Ms. Mia Farrow agreed to serve as UNICEF
Special Representative for Polio Eradication.
She participated with her son Thaddeus, who
had polio, in the launch of UNICEF’s annual
Progress of Nations report that highlighted the
eradication initiative during 1999.  r
Polio Partners
Rotary
International 
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Financial Resource Requirements, 2000-2005
D uring January 1999, the first detailedfinancial resource estimates were com-piled for the Mop-up and Certification
Phase, 2000 – 2005. Paradoxically, the final Mop-
up Phase of the eradication initiative will be the
most expensive due to the intensity of activities,
particularly the necessary house-to-house immu-
nization of large groups of children.
Currently projections are that US $1 billion in
external resources will be needed for polio eradica-
tion activities from 2000 through 2005. Donor
contributions through 2005 are projected at
US $700 million, leaving a US $300 million short-
fall (Figure). Required external resources for the
ten global priority countries for polio eradication
comprise approximately 70% of the US $300 mil-
lion global need. Approximately two-thirds of the
shortfall is required during 2000 through 2002.  r
Figure 6: External resources: Projected contributions by partner agency and shortfall, 2000-2005
United Kingdom
Other*
Rotary International
Canada
SHORTFALL
= US $300 million
World Bank
Belgium
* Italy, Finland, Germany, Aventis-Pasteur, DeBeers
External resource req’d = US $1000m
Received/projected = US $700m
U.S. CDC
USAID
Denmark
Japan
Bill & Melinda Gates Foundation 
UN Foundation
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Challenges and Priorities during the 
Mop-up and Certification Phase, 2000-2005
Polio-free Regions
Ensuring adequate supplies of OPV for NIDs and
Mop-ups
During 1999, an OPV shortfall occurred due to
rapid implementation of accelerated activities (espe-
cially the additional rounds of NIDs in large reser-
voir countries), interruption of production at one
vaccine manufacturer, and rescheduling of large
orders. To ensure the 2000 global OPV supply,
UNICEF made available US $100 million to guar-
antee purchase of the total OPV amount offered in
global tender for 2000. WHO, UNICEF, and man-
ufacturers further streamlined information exchange,
and strengthened vaccine forecasting, planning, and
coordination among UN agencies, vaccine manufac-
turers, and donor governments. However, ongoing
problems with delivery dates and possibly insuffi-
cient total supply are major risks to timely comple-
tion of eradication activities in 2000 and 2001.
Maintaining Political Commitment 
Sustaining political commitment is a major chal-
lenge in the face of a disappearing disease, but is
critical in polio-endemic countries to support the
acceleration of high-quality eradication activities,
and to establish necessary multi-sectoral support.
Some countries, particularly on the African conti-
nent, have stopped NIDs, despite surveillance
sensitivity that remains well below certification
standards. Experience in other Regions has conclu-
sively demonstrated that such actions may jeopar-
dize progress because low-level polio transmission
can continue undetected for more than three years
in areas with sub-optimal surveillance. The longer
that poliovirus transmission continues, the higher
the risk of re-infecting polio-free areas. 
Ensuring Access to All Children
In Conflict Countries: The success of the UN
Secretary-General and other partners in establishing
“Days of Tranquillity” for NIDs during 1999 in DR
Congo demonstrated again the feasibility of work-
ing successfully in conflict-affected areas. These
efforts must be expanded during 2000, drawing
upon the strengths of the UN Secretary-General,
many UN agencies, and other important partners
to promote peace and to support logistical opera-
tions during a cessation of hostilities, particularly in
Afghanistan, Angola, DR Congo, Sierra Leone,
Somalia, and Sudan.
In All Polio-endemic Countries: The slogan
“Every Child Counts” was adopted for the final
push for polio eradication, and to emphasize that all
must be reached and vaccinated. To do so, all
immunization campaigns must be of the highest
quality, and many must include a house-to-house
vaccination strategy to reach all children.
Ensuring Adequate Financial Resources
The projected US $300 million shortfall through
2005 must be rapidly met to ensure that the accel-
eration strategy is not delayed. Delay in achieving
the target date will increase the total cost of eradi-
cation by as much as US $100 million per year. It
will also be difficult to sustain current funding
levels for more than 24-36 months, especially for
polio-free countries that need to continue NIDs to
protect against importations.
Country Priorities
Overcoming obstacles and ensuring the highest
quality of activities in the 30 remaining polio-
endemic countries will be given highest priority.
In particular, efforts will focus upon 17 of 30
countries. ten are “global” priorities because they
face particular challenges requiring multi-year
intensified activities. These countries fall into two
categories:
21
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n “polio virus reservoirs”, where transmission
is particularly intense due to large, dense
populations, low routine immunization cover-
age, and poor sanitation. The countries in this
category are India, Pakistan, DR Congo,
Bangladesh, Nigeria, and Ethiopia.
n countries affected by conflict, where imple-
mentation of vaccination and surveillance
activities is particularly challenging due to
destroyed infrastructure. The countries in this
category are DR Congo, Angola, Afghanistan,
Somalia and Sudan. All have started accelerat-
ed immunization activities.
DR Congo is a special case. As both a global reser-
voir and a country affected by conflict, it faces chal-
lenges inherent to both groups.
Central to the success of polio eradication is ensur-
ing that extra rounds of high-quality NIDs are con-
ducted in 2000 and 2001, particularly in nine of
the ten global priority countries: Afghanistan,
Angola, Bangladesh, DR Congo, India, Nigeria,
Pakistan, Somalia, and the Sudan. In the tenth pri-
ority country, Ethiopia, the critical priority is
achieving certification standard surveillance. 
Regional Priorities
In addition to the global priority countries, within
each WHO Region there are strategic priority
countries that evolve as the polio eradication pro-
gram progresses. At beginning 2000, seven particu-
lar priorities are:
l AFRO: Chad, Congo, Liberia, Niger, Sierra
Leone
l EMRO: Iraq
l SEARO: DPR Korea
Programmatic Priorities
Ensuring High-Quality NID Strategy
Implementation 
A multi-sectoral approach is needed in many coun-
tries to improve the quality of supplementary
immunization activities to ensure that every child is
reached. In PAHO countries, interruption of polio
transmission required the collaborative efforts of all
government agencies, including the armed forces,
to reach and immunize all children. Although more
children are now being vaccinated than ever before,
some are still unreached due to poor microplan-
ning, inadequate social mobilization, and lack of
access due to conflict. During 2000, targeted efforts
will seek to overcome these hurdles, including
augmentation of country-level technical and
administrative capacity. 
High-quality AFP surveillance
Late detection of polio-infected areas can be a con-
sequence of non-certification standard surveillance.
Particularly during the Mop-up Phase of polio erad-
ication, high-quality AFP surveillance is essential to
identify the remaining pockets of polio and to tar-
get immunization activities to break the final chains
of transmission.
Strengthening the Laboratory Network
The laboratory network’s workload will increase
dramatically once countries reach the standard level
of AFP performance, as demonstrated by Nigeria
and India. Laboratories in two important polio-
endemic countries (i.e., Bangladesh and Ethiopia)
have not yet been accredited. While specimens from
these countries do get processed in accredited labo-
ratories elsewhere, it is important that these large
priority countries develop capacity to process stool
specimens. Laboratory accreditation in DPR Korea
is critical.  r
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